This nanocarrier blocks the PD-1/PD-L1 axis to restore CTL cytotoxicity, after which TA is transported into TAMs and MDACs upon release of the lysosomal drug in vitro and in orthotopic HCC models, respectively [95]. The gene discussed is CD274; the disease is hepatocellular carcinoma.